
























of	 patients	 with	 chronic	 heart	 failure	 (CHF)	 of	 ischemic	 genesis	 by	 adding	
potassium	 and	 magnesium	 salts	 of	 gluconic	 acid	 and	 trimetazidine	 to	 the	
background	therapy	(BT).		
Materials	and	methods.	Registration	of	electrocardiogram	(ECG)	and	ECG	







the	 fourth	 group	 consisted	 of	 patients	 treated	 with	 BT	 in	 combination	 with	
potassium	and	magnesium	salts	of	gluconic	acid	and	trimetazidine.	
Results	of	 the	 research.	The	proposed	 treatment	 regimens	were	proved	
to	 be	 effective	 in	 reducing	 ischemic	 parameters	 after	 6	 and	 12	 months	 of	
treatment.	 Anti-ischemic	 treatment	 using	 a	 combination	 of	 potassium	 and	
magnesium	salts	of	gluconic	acid	and	trimetazidine	on	the	background	of	BT	led	
to	 the	most	 significant	 change	 in	 the	average	number	of	myocardial	 ischemia	
episodes	in	examined	patients.	Indicator	of	the	average	daily	number	of	ischemic	
episodes	before	the	research	in	the	first	group	decreased	after	treatment	by	29.21	
%.	The	average	number	of	myocardial	 ischemia	episodes	during	 the	day	 in	 the	
second	group	decreased	by	38.50	%	and	constituted	 (2.78±0.10)	after	 treatment.	
The	addition	of	trimetazidine	to	BT	in	patients	of	III	group	was	accompanied	by	
significant	anti-ischemic	effect	 reducing	 the	average	daily	number	of	 ischemic	
episodes	by	43.8	%	(p<0.001).	It	should	be	noted	that	the	anti-ischemic	treatment	
of	group	IV	patients	using	a	combination	of		BT,	potassium	and	magnesium	salts	
of	gluconic	acid	and	 trimetazidine	 resulted	 in	 the	most	statistically	significant	
change	in	this	indicator	in	examined	patients,	namely	by	48.90	%	(p<0.001).	
Conclusions.	Thus,	a	more	significant	anti-ischemic	effect	was	observed	
when	 using	 combined	 treatment	 with	 potassium	 and	 magnesium	 salts	 of	











most	 important	 problem	 of	 modern	 health	 care	 system	 [9].	 According	 to	 American	 Heart	
Association	 (AHA),	 coronary	 artery	 disease	 (CAD)	 is	 the	 most	 common	 cause	 of	 death	 and	
constitutes	 52%	 in	 the	 structure	 of	 mortality	 from	 cardiovascular	 diseases	 (CVD)	 [7].	 The	 main	
causes	of	mortality	 in	case	of	CAD	are	primarily	acute	myocardial	 infarction	and	sudden	cardiac	
death	[2].	According	to	multicentre	studies	(CONSENSUS,	SOLVD,	ATLAS,	CIBIS,	NETWORK,	ELITE,	
Val-HeFT,	 DIG),	 CAD	 has	 become	 the	 leading	 cause	 of	 heart	 failure,	 it	 was	 detected	 in	 64%	 of	
patients	with	CHF	[9].		
Recently,	 metabolic	 therapy	 has	 become	 one	 of	 the	 directions	 in	 the	 treatment	 of	
coronarogenic	CHF	 [1].	 	This	 is	caused	by	the	fact	that	myocardium	dysfunction	 in	case	of	CHF	of	
ischemic	genesis	is	based	on	intrinsic	cellular	metabolism	disorder	occurring	in	cardiomyocytes	as	
a	result	of	decrease	in	coronary	blood	flow	[9].	Myocardial	reperfusion	develops	after	each	episode	




insufficiency,	 above	 mentioned	 processes	 are	 the	 additional	 pathological	 causes	 along	 with	
hyperactivation	 of	 sympathetic-adrenal,	 renin-angiotensin-aldosterone	 systems,	 activation	 of	
cardial	natriuretic	peptides	secretion,	etc.	in	CHF	development	and	progression	[10].	
Therefore,	the	use	of	drugs	optimizing	energy	exchange	in	the	myocardium,	eliminating	the	
effects	 of	 oxidative	 stress	 and	 other	 metabolic	 disorders	 underlying	 myocardium	 structural	
changes	in	patients	with	CHF	are	pathogenically	caused.	Thus,	the	use	of	gluconic	acid	potassium	
and	 magnesium	 salts	 in	 patients	 with	 MI	 and	 CHF	 may	 be	 one	 of	 pathogenetically	 reasoned	
approaches	 of	 impact	 on	metabolic	 processes,	 energy	 supply	 and	 ionic	homeostasis	 in	 atypical	
myocardial	cells.	
According	to	modern	recommendations,	trimetazidine	is	one	of	the	few	cytoprotectors	that	




myocardial	 infarction	and	quality	of	 life,	but	also	an	 increase	 in	ejection	 fraction	 (approximately	
by	7%)	and	decrease	in	left	ventricular	remodeling	[11].		
The	 largest	 cohort	 study	 (669	 patients)	 on	 the	 use	 of	 trimetazidine	 in	 the	 treatment	 of	
patients	with	CHF	of	ischemic	genesis	detected	a	decrease	within	50%	in	the	risk	of	hospitalization	
because	of	the	disease	exacerbation	[4].	Treatment	with	trimetazidine	was	likely	to	reduce	the	risk	
of	mortality	and	 the	disease	exacerbation	by	11.4%	and	continued	 life	without	complications	 for	
7.8	months	[6].	




The	objective	of	 the	 research	was	 to	 improve	 the	efficiency	of	 treatment	of	patients	with	











patients	with	CHF	and	postinfarction	 cardiosclerosis	were	 examined.	Patients	were	 randomized	
into	 four	 groups	depending	on	 treatment	 characteristics.	The	 first	 group	 included	patients	with	
CHF	after	myocardial	 infarction	with	stenting	who	recieved	BT	 (metoprolol	succinate	 in	a	dose	of	
25	mg/day,	Clopidogrel	 in	a	dose	of	75	mg/day,	cardioaspirin	 in	a	dose	of	75	mg/day,	atorvastatin	
in	a	dose	of	20	mg/day	and	enalapril	in	a	dose	of	5	mg/day)	(n=20).	The	second	group	consisted	of	
patients	 with	 CHF	 after	 myocardial	 infarction,	 who	 were	 treated	 with	 BT	 and	 1	 capsule	 of	
potassium	and	magnesium	salts	of	gluconic	acid	three	times	a	day	(n=21).	The	third	group	included	































































































































































































































































































































and	 reduced	by	48.9%	after	 twelve	months	of	 therapy	 to	2.11	 ±	0.08	 (p<0.001)	being	 significantly	
different	from	similar	index	in	groups	I,	II	and	III.	
The	 average	 and	 maximum	 values	 of	 ST	 segment	 depression	 depth	 were	 analyzed.	
According	 to	 the	 data	 presented	 in	 Table	 2,	 positive	 dynamics	 of	 these	 indices	 reduction	 was	
observed	in	all	groups	of	patients	with	CHF	after	myocardial	infarction	with	performed	reperfusion.	
Twelve	months	treatment	of	group	I	with	BT	drugs	was	accompanied	by	a	decrease	in	the	average	
value	 of	 ST	 segment	 depression	 by	 31.6%	 to	 (0.91	 ±	 0.06)	 mm	 (p<0.001).	 At	 the	 same	 time	 the	
maximum	value	of	ST	segment	depression	decreased	by	26.4%	(p<0.001).	Improved	dynamics	of	ST	
segment	 depression	 depth	 by	 32.5	 %	 and	 54.8%	 was	 observed	 in	 patients	 of	 groups	 II	 and	 III.	
Maximum	ST	segment	depression	decreased	by	25.2	and	42.0%	in	these	groups.		





III	and	 IV	 indicated	 that	 the	 index	was	 significantly	 lower	 in	 comparison	with	BT	 group.	At	 the	
same	 time	 the	 most	 significant	 anti-ischemic	 effect	 was	 observed	 in	 the	 group	 of	 adequate	
combination	anti-ischemic	 therapy	with	 the	use	of	potassium	and	magnesium	 salts	of	 gluconic	
acid	and	 trimetazidine	 (IV	group).	The	use	of	anti-ischemic	 treatment	group	 IV	patients	 led	 to	a	
















1. The	 results	of	ECG	and	ECG	HM	 indicated	 that	 the	 investigated	 treatment	 regimens	were	
effective	in	ischemia	indices	reduction.	
2. Comparing	the	basic	data	and	the	data	from	6	and	12	months	of	patients’	observation,	the	
following	consistent	patterns	were	obtained:	 total	duration	of	 ischemia,	 the	 frequency	of	
the	 daily	 number	 of	 episodes,	 average	 and	 maximum	 ST	 segment	 depression	 depth	
decreased	in	all	four	groups.	




with	 CHF	 of	 ischemic	 genesis	 was	 determined	 to	 be	 appropriate,	 pathogenetically	
reasonable	and	safe.		
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